Sung Won Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sung Won Lee has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
Won Tae Chung
Dong A University
8 shared publicationsSang Yeob Lee
Department of Rhematology, Dong-A University College of Medicine, 3-1 Dongdaesin-Dong, Seo-Gu, Busan, Republic of Korea
7 shared publications- Jung-Yoon Choe
Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
4 shared publications - Junyong Park
Division of Rheumatology, Department of Internal Medicine Dong‐A University College of Medicine Busan Republic of Korea
4 shared publications - Shin-Seok Lee
Division of Rheumatology, Department of Internal Medicine Chonnam National University Medical School and Hospital Gwangju Republic of Korea
4 shared publications - Won Tae Chung
Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea
4 shared publications
Latest Publications
- Open Access
- 10 October 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (10) , 641-648
Efficacy of disease-modifying osteoarthritis drugs in the treatment of osteoarthritis
Background: Osteoarthritis is the most common form of chronic inflammatory arthritis, and its prevalence is steadily increasing owing to its association with aging. Therefore, understanding and implementing appropriate treatments for osteoarthritis in clinical practice is becoming increasingly important. Additionally, there is active research on a new approach for treating osteoarthritis: disease-modifying osteoarthritis drugs (DMOADs).Current Concepts: Several global osteoarthritis treatment guidelines exist; this article introduces the guidelines of the American College of Rheumatology and Osteoarthritis Research Society International, which are among the most widely recognized. A common theme across various guidelines is that exercise and weight loss are the primary recommended treatments. As for pharmacotherapy, the top recommendations include topical nonsteroidal anti-inflammatory drugs (NSAIDs) and oral NSAIDs. Although multiple classes of drugs such as DMOADs are being actively researched to slow the progression of osteoarthritis, no drug has yet been confirmed to be clinically effective or approved for use.Discussion and Conclusion: A deeper understanding of osteoarthritis treatment can help prevent malpractice and improve patient outcomes. While current treatments focus primarily on symptom management, the development of effective DMOADs holds promise for fundamentally altering the disease course and improving joint function and quality of life.
- 10 October 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (10) , 641-648
Open AccessEfficacy of disease-modifying osteoarthritis drugs in the treatment of osteoarthritis
Background: Osteoarthritis is the most common form of chronic inflammatory arthritis, and its prevalence is steadily increasing owing to its association with aging. Therefore, understanding and implementing appropriate treatments for osteoarthritis in clinical practice is becoming increasingly important. Additionally, there is active research on a new approach for treating osteoarthritis: disease-modifying osteoarthritis drugs (DMOADs).Current Concepts: Several global osteoarthritis treatment guidelines exist; this article introduces the guidelines of the American College of Rheumatology and Osteoarthritis Research Society International, which are among the most widely recognized. A common theme across various guidelines is that exercise and weight loss are the primary recommended treatments. As for pharmacotherapy, the top recommendations include topical nonsteroidal anti-inflammatory drugs (NSAIDs) and oral NSAIDs. Although multiple classes of drugs such as DMOADs are being actively researched to slow the progression of osteoarthritis, no drug has yet been confirmed to be clinically effective or approved for use.Discussion and Conclusion: A deeper understanding of osteoarthritis treatment can help prevent malpractice and improve patient outcomes. While current treatments focus primarily on symptom management, the development of effective DMOADs holds promise for fundamentally altering the disease course and improving joint function and quality of life.
- Open Access
- 10 October 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (10) , 616-618
Current issues in osteoarthritis treatment
Background: Osteoarthritis (OA) is the most prevalent chronic joint disorder that leads to pain, disability, and functional impairment. The OA prevalence among those aged ≥65 years in Korea was 30.2% between 2017 and 2021. Owing to a rapidly aging population, OA is becoming a significant public health and socioeconomic concern.Current Concepts: The onset of OA is characterized by cartilage injury, which affects the surrounding tissues and progresses to joint destruction. The pathophysiology varies across joints; hand OA is associated with genetic factors, whereas knee and hip OA are associated with mechanical stress. Nonsteroidal anti-inflammatory drugs are the primary treatment; however, considering their adverse effects and limited efficacy in halting disease progression, further research is warranted for more effective therapies. Natural medicines have been investigated; however, their clinical efficacy is inadequate.Discussion and Conclusion: Currently, no disease-modifying treatments are validated for OA. Animal models fail to reflect the slow progression and complexity of human OA; therefore, drug development remains challenging. In view of increasing healthcare costs and rapid population aging, further research and broader socioeconomic strategies are essential to manage the growing burden of OA.
- 10 October 2024
- Published by Korean Medical Association in Journal of the Korean Medical Association
- Vol. 67 (10) , 616-618
Open AccessCurrent issues in osteoarthritis treatment
Background: Osteoarthritis (OA) is the most prevalent chronic joint disorder that leads to pain, disability, and functional impairment. The OA prevalence among those aged ≥65 years in Korea was 30.2% between 2017 and 2021. Owing to a rapidly aging population, OA is becoming a significant public health and socioeconomic concern.Current Concepts: The onset of OA is characterized by cartilage injury, which affects the surrounding tissues and progresses to joint destruction. The pathophysiology varies across joints; hand OA is associated with genetic factors, whereas knee and hip OA are associated with mechanical stress. Nonsteroidal anti-inflammatory drugs are the primary treatment; however, considering their adverse effects and limited efficacy in halting disease progression, further research is warranted for more effective therapies. Natural medicines have been investigated; however, their clinical efficacy is inadequate.Discussion and Conclusion: Currently, no disease-modifying treatments are validated for OA. Animal models fail to reflect the slow progression and complexity of human OA; therefore, drug development remains challenging. In view of increasing healthcare costs and rapid population aging, further research and broader socioeconomic strategies are essential to manage the growing burden of OA.
- Open Access
- 1 February 2024
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 31 (2) , 68-78
Medical treatment of osteoarthritis: botanical pharmacologic aspect
Junyong Park, M.D., Ph.D., Sung Won Lee, M.D., Ph.D.. J Rheum Dis 2024;31:68-78. https://doi.org/10.4078/jrd.2023.0084
- 1 February 2024
- Published by Korean College of Rheumatology in Journal of Rheumatic Diseases
- Vol. 31 (2) , 68-78
Open AccessMedical treatment of osteoarthritis: botanical pharmacologic aspect
Junyong Park, M.D., Ph.D., Sung Won Lee, M.D., Ph.D.. J Rheum Dis 2024;31:68-78. https://doi.org/10.4078/jrd.2023.0084
- Open Access
Association between oral health and hyperuricemia in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2019
Hyperuricemia plays an essential role in the development of gout. Despite the clinical importance of hyperuricemia, a direct relationship between oral health and hyperuricemia has not been established. Therefore, we aim to investigate the association between oral health and hyperuricemia in Korean adults. We selected 17,584 subjects from the Korea National Health and Nutrition Examination Survey 2016–2019 database. Oral health-related variables included the number of dental caries, regular tooth brushing, use of secondary oral products, and regular dental examination. The odds ratio (OR) and 95% confidence intervals (CIs) for hyperuricemia were calculated using a multivariable-adjusted logistic regression model. In all subjects, oral health status with dental caries and oral health behaviors, including tooth brushing; secondary oral products; and regular dental examination, were significantly associated with hyperuricemia. The adjusted OR and 95% CIs for hyperuricemia comparing more than three dental caries with no dental caries were 1.28 (1.08–1.51). The adjusted OR and 95% CIs for hyperuricemia in regular tooth brushing, use of secondary oral products, and regular dental examination were 0.78 (0.67–0.91), 0.91 (0.82–1.00), and 0.86 (0.78–0.95), respectively. Notably, the association between oral health and hyperuricemia was more prominent in male subjects. In addition, when subjects were grouped by the scoring system regarding oral health, the prevalence of hyperuricemia was lower in groups with a better oral health score. In conclusion, we demonstrated that oral health status and behaviors were associated with hyperuricemia, especially in males. Further complementary studies are needed to confirm the definite association between oral health and hyperuricemia.
Open AccessAssociation between oral health and hyperuricemia in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2019
Hyperuricemia plays an essential role in the development of gout. Despite the clinical importance of hyperuricemia, a direct relationship between oral health and hyperuricemia has not been established. Therefore, we aim to investigate the association between oral health and hyperuricemia in Korean adults. We selected 17,584 subjects from the Korea National Health and Nutrition Examination Survey 2016–2019 database. Oral health-related variables included the number of dental caries, regular tooth brushing, use of secondary oral products, and regular dental examination. The odds ratio (OR) and 95% confidence intervals (CIs) for hyperuricemia were calculated using a multivariable-adjusted logistic regression model. In all subjects, oral health status with dental caries and oral health behaviors, including tooth brushing; secondary oral products; and regular dental examination, were significantly associated with hyperuricemia. The adjusted OR and 95% CIs for hyperuricemia comparing more than three dental caries with no dental caries were 1.28 (1.08–1.51). The adjusted OR and 95% CIs for hyperuricemia in regular tooth brushing, use of secondary oral products, and regular dental examination were 0.78 (0.67–0.91), 0.91 (0.82–1.00), and 0.86 (0.78–0.95), respectively. Notably, the association between oral health and hyperuricemia was more prominent in male subjects. In addition, when subjects were grouped by the scoring system regarding oral health, the prevalence of hyperuricemia was lower in groups with a better oral health score. In conclusion, we demonstrated that oral health status and behaviors were associated with hyperuricemia, especially in males. Further complementary studies are needed to confirm the definite association between oral health and hyperuricemia.
- Open Access
- 11 September 2019
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 20 (1) , 1-7
Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study
Background: We aimed to evaluate the prevalence of foot and/or ankle arthritis (FAA) and its impact on clinical indices in patients with rheumatoid arthritis (RA). Methods: This cross-sectional study used data from the Korean College of Rheumatology Biologics & Targeted therapy registry to observe clinical outcomes of patients undergoing biologics therapy and conventional therapy. FAA was defined as ≥1 tender or swollen joint in the ankle and/or 1st-5th metatarsophalangeal (MTP) joints. Disease Activity Score 28 (DAS28), Routine Assessment of Patient Index Data 3 (RAPID3), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) were assessed. Results: Among 2046 patients, 598 had FAA. The ankle joint was the most commonly involved joint in FAA (tender joint, 71.4%; swollen joint, 59.5%), followed by the third and second MTP joints. Patients with FAA showed higher DAS28, RAPID3, SDAI, and CDAI scores. FAA presence was significantly associated with non-remission as per DAS28-ESR (odds ratio, 3.4; 95% confidence interval, 2.0–5.8), DAS28-CRP (3.6, 2.4–5.3), SDAI (6.3, 2.8–14.6), CDAI (7.6, 2.4–24.3), and RAPID3 (5.6, 2.7–11.5) indices on adjusting for age, sex, disease duration, presence of rheumatoid factor, presence of anti-cyclic citrullinated peptide antibody, lung disease, use of methotrexate, and previous use of biological disease-modifying anti-rheumatic drugs. Patients with FAA were less likely to achieve remission of SDAI (n = 6, 1.0%) and CDAI (n = 3, 0.5%) than that of DAS28-ESR (n = 21, 3.5%), DAS28-CRP (n = 38, 6.4%), and RAPID3 (n = 12, 2.0%). Conclusions: FAA represents a severe disease activity and is an independent risk factor for non-remission in patients with RA.
- 11 September 2019
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 20 (1) , 1-7
Open AccessPrevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study
Background: We aimed to evaluate the prevalence of foot and/or ankle arthritis (FAA) and its impact on clinical indices in patients with rheumatoid arthritis (RA). Methods: This cross-sectional study used data from the Korean College of Rheumatology Biologics & Targeted therapy registry to observe clinical outcomes of patients undergoing biologics therapy and conventional therapy. FAA was defined as ≥1 tender or swollen joint in the ankle and/or 1st-5th metatarsophalangeal (MTP) joints. Disease Activity Score 28 (DAS28), Routine Assessment of Patient Index Data 3 (RAPID3), Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) were assessed. Results: Among 2046 patients, 598 had FAA. The ankle joint was the most commonly involved joint in FAA (tender joint, 71.4%; swollen joint, 59.5%), followed by the third and second MTP joints. Patients with FAA showed higher DAS28, RAPID3, SDAI, and CDAI scores. FAA presence was significantly associated with non-remission as per DAS28-ESR (odds ratio, 3.4; 95% confidence interval, 2.0–5.8), DAS28-CRP (3.6, 2.4–5.3), SDAI (6.3, 2.8–14.6), CDAI (7.6, 2.4–24.3), and RAPID3 (5.6, 2.7–11.5) indices on adjusting for age, sex, disease duration, presence of rheumatoid factor, presence of anti-cyclic citrullinated peptide antibody, lung disease, use of methotrexate, and previous use of biological disease-modifying anti-rheumatic drugs. Patients with FAA were less likely to achieve remission of SDAI (n = 6, 1.0%) and CDAI (n = 3, 0.5%) than that of DAS28-ESR (n = 21, 3.5%), DAS28-CRP (n = 38, 6.4%), and RAPID3 (n = 12, 2.0%). Conclusions: FAA represents a severe disease activity and is an independent risk factor for non-remission in patients with RA.
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (3) , 1260-1266
Palmitate induces lipoapoptosis in Schwann cells through ROS generation-mediated STAMP2 downregulation
- 1 September 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (3) , 1260-1266
Palmitate induces lipoapoptosis in Schwann cells through ROS generation-mediated STAMP2 downregulation
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (52) , e346
Treat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea
Song JJ, et al. J Korean Med Sci. 2018 Nov;33(52):e346. https://doi.org/10.3346/jkms.2018.33.e346
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (52) , e346
Open AccessTreat-to-Target Strategy for Asian Patients with Early Rheumatoid Arthritis: Result of a Multicenter Trial in Korea
Song JJ, et al. J Korean Med Sci. 2018 Nov;33(52):e346. https://doi.org/10.3346/jkms.2018.33.e346
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (33) , e237
Erratum: Correction of Phrase: Risk Factors Associated with Estimated Glomerular Filtration Rate in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis after Treatment with Biological Disease Modifying Anti-Rheumatic Drugs
Lee SW. J Korean Med Sci. 2018 Jun;33(33):e237. https://doi.org/10.3346/jkms.2018.33.e237
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (33) , e237
Open AccessErratum: Correction of Phrase: Risk Factors Associated with Estimated Glomerular Filtration Rate in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis after Treatment with Biological Disease Modifying Anti-Rheumatic Drugs
Lee SW. J Korean Med Sci. 2018 Jun;33(33):e237. https://doi.org/10.3346/jkms.2018.33.e237
- Open Access
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (30) , e214
Risk Factors Associated with Estimated Glomerular Filtration Rate in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis after Treatment with Biological Disease Modifying Anti-Rheumatic Drugs
Lee SW. J Korean Med Sci. 2018 May;33(30):e214. https://doi.org/10.3346/jkms.2018.33.e214
- 1 January 2018
- Published by XMLink in Journal of Korean Medical Science
- Vol. 33 (30) , e214
Open AccessRisk Factors Associated with Estimated Glomerular Filtration Rate in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis after Treatment with Biological Disease Modifying Anti-Rheumatic Drugs
Lee SW. J Korean Med Sci. 2018 May;33(30):e214. https://doi.org/10.3346/jkms.2018.33.e214
- Open Access
- 16 November 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (11) , e0166450
Alpha B-Crystallin Protects Rat Articular Chondrocytes against Casein Kinase II Inhibition-Induced Apoptosis
Although alpha (α)B-crystallin is expressed in articular chondrocytes, little is known about its role in these cells. Protein kinase casein kinase 2 (CK2) inhibition induces articular chondrocyte death. The present study examines whether αB-crystallin exerts anti-apoptotic activity in articular chondrocytes. Primary rat articular chondrocytes were isolated from knee joint slices. Cells were treated with CK2 inhibitors with or without αB-crystallin siRNA. To examine whether the silencing of αB-crystallin sensitizes rat articular chondrocytes to CK2 inhibition-induced apoptosis, we assessed apoptosis by performing viability assays, mitochondrial membrane potential measurements, flow cytometry, nuclear morphology observations, and western blot analysis. To investigate the mechanism by which αB-crystallin modulates the extent of CK2 inhibition-mediated chondrocyte death, we utilized confocal microscopy to observe the subcellular location of αB-crystallin and its phosphorylated forms and performed a co-immunoprecipitation assay to observe the interaction between αB-crystallin and CK2. Immunochemistry was employed to examine αB-crystallin expression in cartilage obtained from rats with experimentally induced osteoarthritis (OA). Our results demonstrated that silencing of αB-crystallin sensitized rat articular chondrocytes to CK2 inhibitor-induced apoptosis. Furthermore, CK2 inhibition modulated the expression and subcellular localization of αB-crystallin and its phosphorylated forms and dissociated αB-crystallin from CK2. The population of rat articular chondrocytes expressing αB-crystallin and its phosphorylated forms was reduced in an experimentally induced rat model of OA. In summary, αB-crystallin protects rat articular chondrocytes against CK2 inhibition-induced apoptosis. αB-crystallin may represent a suitable target for pharmacological interventions to prevent OA.
- 16 November 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (11) , e0166450
Open AccessAlpha B-Crystallin Protects Rat Articular Chondrocytes against Casein Kinase II Inhibition-Induced Apoptosis
Although alpha (α)B-crystallin is expressed in articular chondrocytes, little is known about its role in these cells. Protein kinase casein kinase 2 (CK2) inhibition induces articular chondrocyte death. The present study examines whether αB-crystallin exerts anti-apoptotic activity in articular chondrocytes. Primary rat articular chondrocytes were isolated from knee joint slices. Cells were treated with CK2 inhibitors with or without αB-crystallin siRNA. To examine whether the silencing of αB-crystallin sensitizes rat articular chondrocytes to CK2 inhibition-induced apoptosis, we assessed apoptosis by performing viability assays, mitochondrial membrane potential measurements, flow cytometry, nuclear morphology observations, and western blot analysis. To investigate the mechanism by which αB-crystallin modulates the extent of CK2 inhibition-mediated chondrocyte death, we utilized confocal microscopy to observe the subcellular location of αB-crystallin and its phosphorylated forms and performed a co-immunoprecipitation assay to observe the interaction between αB-crystallin and CK2. Immunochemistry was employed to examine αB-crystallin expression in cartilage obtained from rats with experimentally induced osteoarthritis (OA). Our results demonstrated that silencing of αB-crystallin sensitized rat articular chondrocytes to CK2 inhibitor-induced apoptosis. Furthermore, CK2 inhibition modulated the expression and subcellular localization of αB-crystallin and its phosphorylated forms and dissociated αB-crystallin from CK2. The population of rat articular chondrocytes expressing αB-crystallin and its phosphorylated forms was reduced in an experimentally induced rat model of OA. In summary, αB-crystallin protects rat articular chondrocytes against CK2 inhibition-induced apoptosis. αB-crystallin may represent a suitable target for pharmacological interventions to prevent OA.